1. Home
  2. RGNX
  3. RGNX News

Latest REGENXBIO Inc. (RGNX) News on October 23, 2024

RGNX

MT Newswires

2 days ago

Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
RGNX

PR Newswire

2 days ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
RGNX

PR Newswire

5 days ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc
RGNX

GuruFocus.com

6 days ago

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc

RGNX

Argus Research

14 days ago

RGNX: Rating increased to a HOLD

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
RGNX

PR Newswire

a month ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

RGNX

MT Newswires

a month ago

Regenxbio Names Mitchell Chan CFO

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
RGNX

PR Newswire

a month ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

RegenxBio touts positive data for rare disease drug RGX-121
RGNX

Pharmaceutical Technology

2 months ago

RegenxBio touts positive data for rare disease drug RGX-121

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
RGNX

PR Newswire

2 months ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

2 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

RGNX

Argus Research

2 months ago

RGNX: What does Argus have to say about RGNX?

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
RGNX

PR Newswire

2 months ago

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

RGNX

Argus Research

2 months ago

RGNX: Lowering target price to $12.00

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
RGNX

PR Newswire

2 months ago

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
RGNX

Zacks

3 months ago

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet

REGENXBIO Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
RGNX

Simply Wall St.

3 months ago

REGENXBIO Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
RGNX

Zacks

3 months ago

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates

RGNX

Associated Press Finance

3 months ago

Regenxbio: Q2 Earnings Snapshot

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

3 months ago

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
RGNX

PR Newswire

3 months ago

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX)
RGNX

GuruFocus.com

3 months ago

Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX)

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks
RGNX

TipRanks

3 months ago

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

3 months ago

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

RGNX

Argus Research

3 months ago

RGNX: What does Argus have to say about RGNX?

RGNX

Argus Research

3 months ago

RGNX: Raising target price to $14.00

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
RGNX

Zacks

3 months ago

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?

RGNX

Argus Research

3 months ago

RGNX: What does Argus have to say about RGNX?

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
RGNX

Zacks

3 months ago

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

RGNX

Argus Research

4 months ago

RGNX: Lowering target price to $11.00

Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?
RGNX

Insider Monkey

4 months ago

Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
RGNX

Zacks

4 months ago

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?

RGNX

MT Newswires

4 months ago

Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
RGNX

PR Newswire

4 months ago

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
RGNX

Investor's Business Daily

4 months ago

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
RGNX

Zacks

4 months ago

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

RGNX

MT Newswires

4 months ago

Regenxbio Reports 'Successful' Meeting With FDA For RGX-121

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
RGNX

PR Newswire

4 months ago

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
RGNX

BioPharma Dive

4 months ago

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
RGNX

Zacks

4 months ago

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

RGNX

MT Newswires

4 months ago

Regenxbio Names Curran Simpson President, CEO

Regenxbio CEO to step down after 15 years
RGNX

BioPharma Dive

4 months ago

Regenxbio CEO to step down after 15 years

REGENXBIO Announces Leadership Transition
RGNX

PR Newswire

4 months ago

REGENXBIO Announces Leadership Transition

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
RGNX

PR Newswire

5 months ago

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope
RGNX

Simply Wall St.

5 months ago

It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope

RGNX

MT Newswires

5 months ago

HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating

Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results
RGNX

Simply Wall St.

5 months ago

Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results

Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts
RGNX

GuruFocus.com

5 months ago

Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

5 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript
RGNX

Insider Monkey

5 months ago

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript

RGNX

MT Newswires

5 months ago

UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating

RGNX

Thomson Reuters StreetEvents

5 months ago

Q1 2024 Regenxbio Inc Earnings Call

RGNX

GuruFocus.com

5 months ago

Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
RGNX

Zacks

5 months ago

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

RGNX

Associated Press Finance

5 months ago

Regenxbio: Q1 Earnings Snapshot

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

5 months ago

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

6 months ago

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
RGNX

PR Newswire

6 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

RGNX

Argus Research

6 months ago

RGNX: Lowering target price to $17.00

REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
RGNX

Simply Wall St.

6 months ago

REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures

REGENXBIO Sees Positive Results For Macular Degeneration Therapy
RGNX

Exec Edge

7 months ago

REGENXBIO Sees Positive Results For Macular Degeneration Therapy

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
RGNX

PR Newswire

7 months ago

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
RGNX

PR Newswire

7 months ago

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares
RGNX

GuruFocus.com

7 months ago

Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
RGNX

Motley Fool

7 months ago

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

7 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares
RGNX

GuruFocus.com

8 months ago

Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares

Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates
RGNX

Simply Wall St.

8 months ago

Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
RGNX

PR Newswire

8 months ago

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Announces Proposed Public Offering of Common Stock
RGNX

PR Newswire

8 months ago

REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
RGNX

Zacks

8 months ago

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

Regenxbio data suggest ‘niche’ in Duchenne gene therapy
RGNX

BioPharma Dive

8 months ago

Regenxbio data suggest ‘niche’ in Duchenne gene therapy

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
RGNX

PR Newswire

8 months ago

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
RGNX

PR Newswire

8 months ago

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

RGNX

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Regenxbio Inc Earnings Call

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript
RGNX

Insider Monkey

8 months ago

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
RGNX

Zacks

8 months ago

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights
RGNX

GuruFocus.com

8 months ago

Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights

RGNX

Associated Press Finance

8 months ago

Regenxbio: Q4 Earnings Snapshot

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

8 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

8 months ago

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Regenxbio Inc President and CEO Kenneth Mills Sells 15,000 Shares
RGNX

GuruFocus.com

8 months ago

Regenxbio Inc President and CEO Kenneth Mills Sells 15,000 Shares

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
RGNX

Zacks

8 months ago

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO

Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
RGNX

Zacks

8 months ago

Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
RGNX

Zacks

8 months ago

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?
RGNX

Zacks

8 months ago

Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
RGNX

PR Newswire

9 months ago

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
RGNX

PR Newswire

9 months ago

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

Ramaco Announces Hiring of Distinguished West Virginian as New General Counsel; First Quarter 2024 Class B Dividend Declared
RGNX

PR Newswire

9 months ago

Ramaco Announces Hiring of Distinguished West Virginian as New General Counsel; First Quarter 2024 Class B Dividend Declared

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
RGNX

Zacks

9 months ago

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

RGNX

Business Wire

9 months ago

B&G Foods Releases Inaugural Corporate Social Responsibility Report

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
RGNX

PR Newswire

9 months ago

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

Should You Hold Seneca Foods Corporation (SENEA)?
RGNX

Insider Monkey

9 months ago

Should You Hold Seneca Foods Corporation (SENEA)?

Byline Bancorp, Inc. (NYSE:BY) Q4 2023 Earnings Call Transcript
RGNX

Insider Monkey

9 months ago

Byline Bancorp, Inc. (NYSE:BY) Q4 2023 Earnings Call Transcript

Alpha and Omega Semiconductor Announces Closing of DOJ Investigation
RGNX

Business Wire

9 months ago

Alpha and Omega Semiconductor Announces Closing of DOJ Investigation

MetroCity Bankshares, Inc. (NASDAQ:MCBS) Looks Interesting, And It's About To Pay A Dividend
RGNX

Simply Wall St.

9 months ago

MetroCity Bankshares, Inc. (NASDAQ:MCBS) Looks Interesting, And It's About To Pay A Dividend

Ethan Allen Reports Fiscal 2024 Second Quarter Results Highlighted by Strong Margins and Robust Balance Sheet; Lower Sales Reflect Post Pandemic Economy
RGNX

GlobeNewswire

9 months ago

Ethan Allen Reports Fiscal 2024 Second Quarter Results Highlighted by Strong Margins and Robust Balance Sheet; Lower Sales Reflect Post Pandemic Economy

Yext Recognized by Built In as a 2024 Best Place To Work
RGNX

Business Wire

9 months ago

Yext Recognized by Built In as a 2024 Best Place To Work

The Road Less Traveled: 3 Stocks to Sell as the Electric Vehicle Market Stalls
RGNX

InvestorPlace

9 months ago

The Road Less Traveled: 3 Stocks to Sell as the Electric Vehicle Market Stalls

Soleno Therapeutics Strengthens Leadership Team with Key Appointments
RGNX

GlobeNewswire

9 months ago

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Share on Social Networks: